Adam is an experienced IP litigator who primarily serves pharmaceutical, medical, high tech, and defense industry clients. He handles patent, trademark, and trade secret matters for innovators and investors. Adam has a strong record of success in multiparty, highly contested Hatch-Waxman litigation, in addition to other litigations involving advanced biochemistry, polymers, optics, manufacturing processes, and electronics. He has tried cases before multiple US district courts, briefed and argued cases before the US Court of Appeals for the Federal Circuit, and briefed bet-the-company issues before the US Supreme Court.
Adam’s practice focuses on intellectual property litigation. He handles patent, trademark, and trade secret matters on behalf of innovators and investors in a range of industries. His core practice includes patent and trade secret litigation involving complex technologies in the pharmaceutical, medical, high-tech, and defense industries. Adam has tried cases before multiple US District Courts, briefed and argued cases before the US Court of Appeals for the Federal Circuit, and has briefed bet-the-company issues before the US Supreme Court.
For pharmaceutical clients, Adam leverages his trial and appellate experience in litigation when advising on new product development, regulatory strategy, Orange Book listing, citizen petition practice, and the settlement of multiparty, highly contested Hatch-Waxman litigation. Adam regularly conducts due diligence on blockbuster pharmaceutical assets, including reviewing and assessing litigation, regulatory, and competitive strategies.
Prior to joining the firm, he was a partner in the Boston office of another international law firm.
More Legal and Business Bylines From Adam P. Samansky
- Plaintiff Can Assert Patent Infringement and Seek Injunctive Relief in Second-Phase BPCIA Litigation Per Illinois District Court Decision - (Posted On Thursday, February 24, 2022)
- D. Del. Says ANDA Specification Trumps All Else in Infringement Analysis - (Posted On Thursday, February 17, 2022)
- California District Court Sides with Majority Position, Dismissing Willful and Induced Infringement Claims that Relied on Original Complaint for Knowledge of Asserted Patent - (Posted On Tuesday, February 08, 2022)
- Trade Secret Misappropriation Not Sufficiently Plead Where Defendant Possessed but did Not Threaten to Disclose Trade Secret Information in Southern District of New York Case - (Posted On Tuesday, January 25, 2022)
- Federal Circuit Affirms Dismissal of Hatch-Waxman Defendants for Lack of Venue and Failure to State a Claim - (Posted On Friday, November 12, 2021)
- Federal Circuit Clarifies that Willful Infringement Does Not Require Egregious Conduct - (Posted On Tuesday, October 26, 2021)
- N.D. Ill. Finds that a Foreign Parent Corp. May be Sued Under BPCIA Without the U.S. Subsidiary that Signed and Filed aBLA - (Posted On Tuesday, September 21, 2021)
- Federal Circuit Reiterates Requirement under § 287 that Alleged Infringers have Notice of Specific Alleged Infringement - (Posted On Thursday, September 09, 2021)
- Nonobviousness of Commercially Successful Designs: Mmm, Mmm, Not So Fast - (Posted On Tuesday, August 31, 2021)
- District of Delaware Recites Policy Rationale for Dismissing Willful and Indirect Infringement Claims for Failure to Plead Pre-Suit Knowledge of Infringement - (Posted On Monday, April 05, 2021)